remain restrict bayer due role anim health dispos may publish
forecast continu oper price target rate
bayer report result line expect sale underli ebitda
see guidanc undemand ex china impact given lack margin
progress rebound year crop pharma xarelto eylea presum
near peak profit littl improv confid reiter
vs guidanc remain cautiou pharma busi cs
consensu sale profit howev continu believ bayer
market lead crop scienc busi high qualiti asset broad pipelin
note guidanc current exclud possibl impact coronaviru area
expect investor focu given strong china growth expect
updat result
pharma forecast growth lower end guidanc reflect
expect slow uptak nubeqa evidenc poor us prescript data
date despit commentari strong earli access achiev payer well
modest launch far vitrakvi
litig number glyphos case rose less expect
howev still await news possibl settlement outcom
three on-going appeal case cs continu assum glyphos
litig cost see on-going dicamba litig much less signific
catalyst risk updat glyphos global settlement appeal court verdict
june finerenon fidelio-dkd top-line data ckd
valuat metric
price-to-earnings rel local market
number share
price rel chart measur perform
deutsch bors dax close
spot exchang rate
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek busi
compani cover research report result investor awar firm may conflict interest could
affect object report investor consid report singl factor make invest decis
share wtd average mn
ratio valuat
price book
return equiti state
net debt ebitda
price rel chart measur perform deutsch bors dax
close
spot exchang rate
profit tax
associ
chang work capit
cash non-cash item
flow oper
free cash-flow firm
flow invest
issuanc retir debt
cash-flow financ
effect exchang rate
chang net cash/debt
net debt start
chang net debt
net debt end
intang asset goodwil
total equiti liabil
nubeqa whilst see nubeqa us launch disappoint far base us rx
trend uptak appar hinder need pre-identif patient
potenti sign encourag nubeqa channel check suggest
secur competit commerci coverag par erleada well recent
posit os data await detail bayer expect roll extens
free trial program month free program zero dollar co-pay commerci patient
although expect medicar access remain limit nubeqa also recent post
posit os data arami trial ahead competitor despit start
relev studi year later peer bayer indic patient nubeqa trial
less sick compar competitor trial although note bayer /orion
exclud patient seizur
xarelto prescript trend good overal howev iqvia show compass
dose yet pick us remain less recent script
understand ex-u uptak compass indic also slow bayer
comment educ effort need increas usag howev note
strong perform spaf indic exu signific contribut china
russia europ also see evid greater price competit us
bayer receiv effect royalti move bmi highlight
increas rebat eliqui key driver group overal higher rebat level
rose across full us portfolio
eylea bayer right eylea outsid us price competit arguabl
weaker much limit use label avastin account believ
around us volum recent expert call see transcript takeaway dr
paul grigg express view beovu could displac eylea standard care
signific number patient base abil dri eye felt
best predictor long term benefit also report issu inflamm
practic possibl initi inflamm resolv second visit howev
note american societi retin specialist asr recent flag
incid vascul whilst think observ rate vascul low think
observ may slow european adopt approv expect
bayer histor cautiou growth prospect eylea given high
penetr europ go accept compound avastin use
china annual report show market sale china
whole group bayer particip latest round tender lead
diabet drug glucobay appar undercut local tender price
cut yuan per tablet us cent time lower price partial
boost increas volum assum declin base
estim sale made specif coronaviru assumpt
lower em sale expect pharma consum
key question pharma busi bayer replenish
pipelin forecast low singl digit sale growth
xarelto goe patent europ eylea competit step despit expect
extra us end user sale recent patent settlement xarelto
give bayer addit royalti incom period
question whether bayer would want/b abl part signific
amount cash whilst overhang expect multi-billion dollar glyphos
corn soy crop perform expect rebound strongli poor
plant condit earli season conting normalis weather
condit anticip cost synergi monsanto acquisit reach
expect bayer overal save expect
whilst potenti neg mix effect form greater volum uplift
less profit soy acr corn acr see larg irrelev
given overal magnitud acreag increas
assumpt result yoy forecast ebita-pr growth
global ag colleagu forecast increas corn acr plant
acr last season increas soy acr plant
acr last season recal prior us soy crop neg impact predominantli
us/china trade fear african swine fever asf demand front well
unpreced weather us spring plant season natur market
monitor potenti chines ag purchas affect coronaviru fear
though chines govern take measur improv flow feed protein
market bottom line expect materi yr/yr increas us plant soy acreag
believ risk still exist global demand front
bayer manag said expect flat corn seed price soy bean price
slightli addit discount expect february/march due
normal competit dynam ahead plant us ag team expect soy neg
mid-singl digit probabl flat corn price fairli low slightli
neg like global bayer seed/trait revenu deriv corn
soy balanc veget cotton
valu corn vs soy overal see corn profit group take
account seed trait associ crop protect understand direct sale
corn seed bring roughli doubl revenu per acr vs soy soy licens
trait highli profit believ slightli lower corn seed trait ebitda
margin base histor monsanto margin us season off-set
higher associ crop protect revenu get corn
ag team detail us primer contain market outlook seed
crop protect estim current dynam suggest corn acreag
rang soy rang depend heavili trade/asf/pl
condit follow monthli plant updat wasd data
build march usda prospect plant report march next
key forward look catalyst anticip fairli healthi end carri
estim potenti headwind price base yoy plant acreag increas
averag boost trend line yield estim uncertain demand note usda
gave initi outlook statement forecast crop year last week
corn acr soy acr
cagrc guidancec salesgroup currenc portfolio ebitda pre special growth currenc portfolio margin ep cont fx benefit sale fx benefit financialsgroup ppe/intang result tax tax raterestructur /special item ebitda level debt cash charl martineau univers toronto februari
cagrc guidancec growth fx special fx underli fx special fx sciencedivsion currenc portfolio special currenc portfolio adjust ebitda underli charl martineau univers toronto februari
chang forecast
pharma rais sale eylea given recent neg news flow compet drug
beovu reflect increas market share eylea also slightli posit
kogen sale given stabl sale face grow hemlibra sale modestli
cut xofigo sale reflect lower sale impli drug exclus
best-sel product tabl cutoff sale
crop scienc cut crop earn reflect reinvest rais
earn year line guidanc ebitda margin
net effect chang broadli flat group ebitda pre
howev cut core ep averag reflect higher
figur chang forecast new vs old
key issu stock remain on-going glyphos litig long take
settl cost expect see signific ramp number
glyphos case file fy result howev bayer report
modest step number file case contrast comment made
settlement mediat ken feinberg januari reuters/bloomberg jan
estim around roundup lawsuit could close settlement
settlement cost estim assum later file case less like meet settlement
pay-out criteria view figur
bayer reiter call import abl settl reason closur
time frame compani point toward settlement
figur number glyphos case
one key question whether juri verdict appeal verdict
reach settlement johnson appeal soonest conclud
court indic march/april deadlin final oral argument follow day
period thereaft conclud appeal
unsur promot recent cancel wade case whether
reflect confidenti settlement involv parti convinc
progress made global settlement howev accord usrtk report
carey gillam sourc involv litig said certain plaintiff
agre cancel trial secur agreement specif settlement amount
parti said discuss deal conting upon success
complet larger overal settlement us litig cs assum litig
understand next trial berliant case slate start may
marin counti superior court california case grant prefer statu
expedit trial due plaintiff critic ill condit
broughtglyphos case broughtc projectionstrong claimparti claiminvalid claimplaintiff estim valid claim per case settlement contribut insur cover estim charg case settlement trust-fund assumpt total glyphos litig charg eur charl martineau univers toronto februari
deliv guidanc sale vs ebitda vs
deliveri deliv
crop solid perform impact challeng market crop integr success
consum top-line growth achiev turnaround track
effici programm synergi realiz track includ
crop achiev one year ahead plan
portfolio currenta copperton dr scholl derma divest close anim health
close
updat glyphos litig convinc safeti profil glyphos plaintiff
reflect merit litig appeal underway consid
settlement financi reason
crop scienc sale ebitda special item
growth impact advers busi condit north america result miss
herbicid corn
growth across corn seed trait well insecticid fungicid market
environ soy challeng
strong increas ebitda special item result acquisit cost
synergi integr
cost synergi deliv target
innov pipelin peak sale valu
pharma sale yoy ebitda special item
xarelto driven higher volume china eu russia eylea volume
increas region grew
china growth growth emea uk germani
ebitda special item increas driven good volum growth
approv cancer drug vitrakvi grant eu recent nubeqa first drug
show os differenti safeti profil label updat xarelto
forecast peak sale
acquisit bluerock invest centuri
establish posit self-renew stem cell therapi
consum return sale profit growth sale ebitda
emea asia/pacif latin america posit growth
effici gain compens miss earn contribut divest busi
led ebitda special item py level
north america share consum sale
support smallhold farmer low- middle-incom countri lmic
provid women low- middl incom countri access modern
expand access everyday health peopl underserv commun around
make oper carbon neutral work supplier reduc
emiss across valu chain
sale adj constant currenc portfolio effect
fx posit impact
free flow increas driven overal posit oper develop
target achiev
ebitda-margin special item
includ impact coronaviru better guid end updat
posit rebound advers weather america continu sale cost synergi
growth new product
posit growth xarelto eylea tight cost control
neg valu base price china
posit top-lin growth realiz full effect portfolio measur
execut effici measur
deliv oper target
crop grow market margin improv
pharma deliv sale margin expans launch nubeqa vitrakvi
launch prepar vericiguat finerenon
execut effici improv program realiz synergi
portfolio close anim health sale
 push pull us plant season
nomin sale growth forecast translat sale biggest part growth
rebound us expect addit acr versu previou year plant due
bad weather acr corn soya bean ratio depend weather
trade condit account addit sale growth new
product region fungicid insecticid corn probabl ball park addit
sale sale synergi relev countri identifi us latin america canada mexico
give addit total head wind us one clear
one sale agreement basf previou year less half
year half year loss crop protect emea low singl digit price
declin soya us get us net-net forecast
 new launch pharma nubeqa vitrakvi
disclos detail number nubeqa approv juli ahead pdufa far
start line expect number far patient enrol program
offer month free trial major physician taken advantag program
convinc data present one remark thing third
class first demonstr os follow strong indic
efficaci reflect market research also find back access report
overal coverag live across board us commerci
live almost medicar part live realli signific agent requir
step edit broad adopt vitrakvi small popul continu look patient
publish data lancet efficaci extrem convinc orr subject
strong pediatr mpf month mo consist favour
safeti profil come market research make good progress give littl
mid-year market research show free program go come
 xarelto china impact vbp
xarelto part vbp outstand xarelto extrem pleas
volum overal valu expans china alon increas
 vbp bake assumpt glucobay avelox
built vbp guidanc includ glucobay avelox expect effect
assum corona lead delay vbp
 vericiguat think cardiologist think moa add entresto
finerenon dkd impact
excit vericiguat posit top-lin studi present upcom get
qualit impact doc studi frail difficult popul think see
place guidelin studi mix patient pre-treat entresto
treatment dont see limit top entresto tune
much detail finerenon offer good option impair renal function
differ moa go patient type background studi popul
typic represent market share patient
 signific chang supervisori board interpret anyth strategi
strategi commun continu execut chairman step
commun yesterday explain driven stay year longer
want beyond maximum age supervisori board member realloc bear
strateg relev adjust base chang valu floor fulli integr crop
scienc thing technic effect
 updat xarelto us ip settlement
daili expir feb challeng other relev parti
enter settlement agreement grant licens market
begin shorten patent life give us exclus
 nubeqa share new patient abl achiev see reduct
level
happi see comment
 level reinvest crop much bring margin gain
net ebita synergi fall bottom line cumul synergi
achiev year track help beyond sale growth keep us
track midterm guidanc ebitda
 see anyth glyphos product impact china due coronaviru raw
materi cost
see impact glyphos price come china rel low yet see
price increas limit suppli sure come raw materi neg
impact cog come china clean initi within china year
expect net-net posit cog develop due cost synergi
 us seed help us understand contain price competit soy
differ demand suppli situat overal soy bean still situat demand
suppress combin africa swine fever us china trade conflict paper
partial settl practic impact know suppli side competit
situat price weaker corn robust demand competit situat
better situat rel soy achiev price uplift
 media comment around need rais fund settlement
ambiti target hit de lever dividend
modest time valu perspect well divest anim health mid-
year proce cash rest equiti translat cash assum
 glyphos settlement window close
said qualifi type solut need financi reason
accept bring closur overal litig think also right way take
negoti time help driven find best solut compani
sharehold take long take
 xarelto date appli parti opportun extens
parti work dilig get align date make good
progress europ patent expir jan revok origin eu patent offic first instanc
appeal still appeal
 highlight limit exposur pharma us thought enhanc posit us
time-frame
lucki posit extend right finerenon allow us establish posit
us choos right co-promot across world vericiguat give us two
competit product bag close time continu oncolog franchis
give us room establish broad footprint strong posit women health hemophilia
come good time chines domin go less go forward
 outlook eylea see competit beovu
high singl digit see beovu feel stronger clinic
profil market posit launch us on-going make lot nois nois
good
 acceler uptak xarelto pad/cad
super happi start one thing come posit
voyag data give us chanc add data patient see
make patient profil even clear remain hope boost sale
 competitor headwind soya bean price digit impact brand specif
board base bran specif impact digit channel overal suppress demand
rel high suppli natur reaction market one specif region seed
compani competit platform discount quit heavili direct
follow impact price market driven region player digit
 round case increas less expect think
develop number could plateau
report current statu specul mani unfil add colour
develop case depend number factor one promot
activ plaintiff come quit bit that seen lower build
dynam
 pharma margin target push pull
look busi china vbp cost launch prepar
finerenon nubeqa vitrakvi chang cost alloc dont think
 work capit manag driver elabor
becom import us put incent system alway pocket
optim opportun busi busi receiv inventori see
signific opportun alloc chang give us pro forma impact ebitda margin
import reflect model
bayer us end user sale restat exclud oper item rate discont net net share except ep ops- special item inc special item report per peak sale data bayer book share end user charl martineau univers toronto februari
compani mention price
